Cancer, infectious diseases, and metabolic and hereditary genetic disorders are a global
health burden affecting millions of people, with contemporary treatments offering limited …

Abstract The last decade (2013–2023) has seen unprecedented successes in the clinical
translation of therapeutic antisense oligonucleotides (ASOs). Eight such molecules have …

The severity of Alzheimer9s disease (AD) progression involves a complex interplay of
genetics, age, and environmental factors orchestrated by histone acetyltransferase (HAT) …

Background Alternative splicing (AS), a posttranscriptional process, contributes to the
complexity of transcripts from a limited number of genes in a genome, and AS is considered …

Phosphorodiamidate morpholino oligomers (PMOs) are a special type of antisense
oligonucleotides (ASOs) that can be used as therapeutic modulators of pre-mRNA splicing …

Simple Summary The Shitou goose, the largest cultivated goose breed in China, has high
research value in meat traits. Muscle development is regulated by genes related to myoblast …

Alternative splicing accounts for a considerable portion of transcriptomic diversity, as most
protein-coding genes are spliced into multiple mRNA isoforms. However, errors in splicing …

Simple Summary BCAS1-SV1, a novel splice variant of BCAS1, promotes the proliferation
and migration of glioblastoma cells by directly binding to and inhibiting the tumor suppressor …

Oligonucleotides hold great promise as therapeutic agents but poor bioavailability limits
their utility. Hence, new analogues with improved cell uptake are urgently needed. Here, we …

Simple Summary Antisense oligonucleotide (ASO)-based drugs are a new class of
compounds. In this review, we will discuss ASO technology, including improved delivery …